Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 26, Issue 12, 2016, Pages 1071-1078

  Luconi, M ^a   Raimondi, L ^b   Di Franco, A ^a   Mannucci, E ^a,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cardio protection; Empagliflozin; SGLT2 inhibitors; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; ERYTHROPOIETIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; SAXAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 1; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEMATOCRIT; HOSPITALIZATION; HUMAN; KETOGENESIS; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HEART; KIDNEY; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ANIMALS; BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEART; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MYOCYTES, CARDIAC; RISK ASSESSMENT; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS; TREATMENT OUTCOME;

EID: 84999273609     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2016.09.001     Document Type: Review

References (67)

1. [1] U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for industry diabetes mellitus — evaluating cardio vascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008 Available online at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
2. [2] Kappel, B.A., Marx, N., Federici, M., Oral hypoglycemic agents and the heart failure conundrum: lessons from and for outcome trials. Nutr Metab Cardiovasc Dis 25 (2015), 697–705.
3. [3] Bonadonna, R.C., Borghi, C., Consoli, A., Volpe, M., Novel antidiabetic drugs and CR: primum non nocere. Nutr Metab Cardiovasc Dis 26 (2016), 759–766.
4. [4] Coch, R.W., Green, J.B., Current cardiovascular outcomes trials in type 2 diabetes: perspectives and insight. Nutr Metab Cardiovasc Dis 26 (2016), 767–772.
5. [5] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
6. [6] The Lancet Diabetes Endocrinology, Getting to the heart of the matter in type 2 diabetes. Lancet Diabetes Endocrinol, 3, 2015, 827.
7. [7] Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D., McMurray, J.J., SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339.
8. [8] http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Public_assessment_report/human/002677/WC500168594.pdf.
9. [9] Sonesson, C., Johansson, P.A., Johnsson, E., Gause-Nilsson, I., Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol, 15, 2016, 37.
10. [10] http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002322/WC500136024.pdf.
11. [11] http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002649/WC500156457.pdf.
12. [12] http://www.clinicaltrials.gov.
13. [13] Mannucci, E., Monami, M., Lamanna, C., Gori, F., Marchionni, N., Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 19 (2009), 604–612.
14. [14] Del Prato, S., Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia 52 (2009), 1219–1226.
15. [15] van der Heijden, A.A., Ortegon, M.M., Niessen, L.W., Nijpels, G., Dekker, J.M., Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: the Hoorn Study. Diabetes Care 32 (2009), 2094–2098.
16. [16] Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U.C., et al. EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38 (2015), 420–428.
17. [17] Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S., Woerle, H.J., Broedl, U.C., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 1180–1193.
18. [18] Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159 (2013), 262–274.
19. [19] UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998), 703–713.
20. [20] Stevens, R.J., Kothari, V., Adler, A.I., Stratton, I.M., United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 101 (2001), 671–679.
21. [21] Inzucchi, S.E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12 (2015), 90–100.
22. [22] Yusuf, S., Hawken, S., Ounpuu, S., Bautista, L., Franzosi, M.G., Commerford, P., et al., INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366 (2005), 1640–1649.
23. ® trial. Eur Heart J 37 (2016), 1526–1534.
24. [24] Alva, M.L., Gray, A., Mihaylova, B., Leal, J., Holman, R.R., The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med 32 (2015), 459–466.
25. [25] Dormandy, J.A., Charbonnel, B., Eckland, D.J., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
26. [26] Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
27. [27] White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., et al., EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
28. [28] Zannad, F., Cannon, C.P., Cushman, W.C., Bakris, G.L., Menon, V., Perez, A.T., et al., EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
29. [29] Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al., TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 373 (2015), 232–242.
30. [30] Fadini, G.P., Albiero, M., Avogaro, A., Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence. Vasc Pharmacol 73 (2015), 1–3.
31. [31] Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA, 288, 2002.
32. [32] Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65 (2016), 1190–1195.
33. [33] Taylor, S.I., Blau, J.E., Rother KI.SGLT2i may predispose to ketoacidosis. J Clin Endocrinol Metab 100 (2015), 2849–2852.
34. [34] Peters, A.L., Buschur, E.O., Buse, J.B., Cohan, P., Diner, J.C., Hirsch, I.B., Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693.
35. [35] Sato, K., Kashiwaya, Y., Keon, C.A., Tsuchiya, N., King, M.T., Radda, G.K., et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J 9 (1995), 651–658.
36. [36] Sacks, F.M., Carey, V.J., Anderson, C.A., Miller, E.R. 3rd, Copeland, T., Charleston, J., et al. Effects of high vs low glycemic index of dietary carbohydrate on cardiovascular disease risk factors and insulin sensitivity: the OmniCarb randomized clinical trial. JAMA 312:23 (2014 Dec 17), 2531–2541.
37. [37] Mudaliar, S., Polidori, D., Zambrowicz, B., Henry, R.R., Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 38 (2015), 2344–2353.
38. [38] Owen, N.E., Ridge KM.Mechanism of angiotensin II stimulation of Na-K-Cl cotransport of vascular smooth muscle cells. Am J Physiol 257 (1989), C629–C636.
39. [39] Bailey, C.J., Gross, J.L., Pieters, A., Bastien, A., List, J.F., Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375 (2010), 2223–2233.
40. [40] Lambert, R., Srodulski, S., Peng, X., Margulies, K.B., Despa, F., Despa, S., Intracellular Na+ concentration ([Na+]i) is elevated in diabetic hearts due to enhanced Na+-Glucose cotransport. J Am Heart Assoc, 4, 2015, e002183.
41. [41] Heerspink HJ1, Lambers, de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
42. [42] Kang, J., Park, J., Lee, J.M., Park, J.J., Choi, D.J., The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: a meta-analysis of randomized clinical trials. Int J Cardiol 218 (2016), 12–22.
43. [43] Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124 (2014), 499–508.
44. [44] Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21 (2015), 512–517.
45. [45] Ali, S., Ussher, J.R., Baggio, L.L., Kabir, M.G., Charron, M.J., Ilkayeva, O., et al. Myocardiocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol Metab 4 (2014), 132–143.
46. [46] Méry, P.F., Brechler, V., Pavoine, C., Pecker, F., Fischmeister, R., Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature 345 (1990), 158–161 Wilkerson RD, Partlow DB, Pruett JK, Patterson CW. A possible mechanism of the antiarrhythmic action of glucagon. Eur J Pharmacol. 1977;44:57-63.
47. [47] Wilkerson, R.D., Partlow, D.B., Pruett, J.K., Patterson, C.W., A possible mechanism of the antiarrhythmic action of glucagon. Eur J Pharmacol 44 (1977), 57–63.
48. [48] Ceriello, A., Genovese, S., Mannucci, E., Gronda, E., Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol 3 (2015), 929–930.
49. [49] Retnakaran, R., Kramer, C.K., Choi, H., Swaminathan, B., Zinman, B., Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 37 (2014), 3270–3278.
50. [50] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al., LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:4 (2016), 311–322.
51. [51] Schmaier, A.H., The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol 285 (2003), R1–R13.
52. [52] Muskiet, M.H., van Raalte, D.H., van Bommel, E.J., Smits, M.M., Tonneijck, L., Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol 3 (2015), 928–929.
53. [53] Zhou, L., Cryan, E.V., D'Andrea, M.R., Belkowski, S., Conway, B.R., Demarest, K.T., Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem 90 (2003), 339–346.
54. [54] Vrhovac, I., Balen Eror, D., Klessen, D., Burger, C., Breljak, D., Kraus, O., et al. Localizations of Na[+]-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 467 (2015), 1881–1898.
55. [55] Banerjee, S.K., McGaffin, K.R., Pastor-Soler, N.M., Ahmad, F., SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 84 (2009), 111–118.
56. [56] Aerni-Flessner, L., Abi-Jaoude, M., Koenig, A., Payne, M., Hruz, P.W., GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle. Cardiovasc Diabetol, 11, 2012, 63.
57. [57] Russell, R.R. 3rd, Li, J., Coven, D.L., Pypaert, M., Zechner, C., Palmeri, M., et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114 (2004), 495–503.
58. [58] Arad, M., Benson, D.W., Perez-Atayde, A.R., McKenna, W.J., Sparks, E.A., Kanter, R.J., et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 109 (2002), 357–362.
59. [59] Ramratnam, M., Sharma, R.K., D'Auria, S., Jung Lee, S., Wang, D., Yin, N.X.H., et al. Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J Am Heart Assoc, 3, 2014 pii: e000899.
60. [60] von Lewinski, D., Kockskämper, J., Rübertus, S.U., Zhu, D., Schmitto, J.D., Schöndube, F.A., et al. Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium. Eur J Heart Fail 10 (2008), 1172–1176.
61. [61] Balteau, M., Tajeddine, N., de Meester, C., Ginion, A., Des Rosiers, C., Brady, N.R., et al. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res 92 (2011), 237–246.
62. [62] Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D.E., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14 (2012), 83–90.
63. [63] Heise, T., Seewaldt-Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 15 (2013), 613–621.
64. [64] Rosenstock, J., Cefalu, W.T., Lapuerta, P., Zambrowicz, B., Ogbaa, I., Banks, P., et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care 38 (2015), 431–438.
65. [65] Powell, D.R., Smith, M., Greer, J., Harris, A., Zhao, S., DaCosta, C., et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 345 (2013), 250–259.
66. [66] Trial Investigators, O.R.I.G.I.N., Gerstein, H.C., Bosch, J., Dagenais, G.R., Díaz, R., Jung, H., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367 (2012), 319–328.
67. [67] Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Køber, L.V., et al. ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.